Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Dexamethasone adjuvant therapy and intramuscular ceftriaxone in bacterial meningitis amongst adults in an area of high human immunodeficiency virus (HIV) prevalence in Blantyre, Malawi
ISRCTN ISRCTN31371499
ClinicalTrials.gov identifier
Public title Dexamethasone adjuvant therapy and intramuscular ceftriaxone in bacterial meningitis amongst adults in an area of high human immunodeficiency virus (HIV) prevalence in Blantyre, Malawi
Scientific title
Acronym SAM Trial (Steroids in Adult Meningitis)
Serial number at source P.98/99/30R
Study hypothesis 1. Dexamethasone, by limiting the host inflammatory response in bacterial meningitis, will reduce mortality and morbidity
2. Ceftriaxone is as effective given intramuscularly (IM) as it is when given intravenously (IV) and may therefore be used in rural areas where IV therapy is unavailable
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Malawi
Disease/condition/study domain Bacterial Meningitis
Participants - inclusion criteria All adults admitted to the Queen Elizabeth Central Hospital, Blantyre with a preliminary diagnosis of bacterial meningitis.
Participants - exclusion criteria 1. Age less than 16 years
2. Steroids received within the 24 hours preceeding admission
Anticipated start date 15/05/2002
Anticipated end date 31/01/2005
Status of trial Completed
Patient information material
Target number of participants 420
Interventions Dexamethasone 16 mg twice daily for 4 days versus placebo.
Ceftriaxone 2 mg twice daily for ten days given either IV or IM.
Primary outcome measure(s) Mortality at 40 days
Secondary outcome measure(s) 1. Death or disability at 40 days
2. Clinically apparent hearing loss at 40 days
3. Death at six months
Sources of funding Meningitis Research Foundation (UK)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=Retrieve&list_uids=18077809
Contact name Dr  Matthew  Scarborough
  Address 27 Oatlands Rd
  City/town Oxford
  Zip/Postcode OX2 0EU
  Country United Kingdom
  Email mattscar@talktalk.net
Sponsor College of Medicine Research Committee (Malawi)
  Address Private Bag 360
Chichiri
  City/town Blantyre
  Zip/Postcode BT3
  Country Malawi
Date applied 16/08/2005
Last edited 18/12/2007
Date ISRCTN assigned 07/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central